%0 Journal Article
%A Gavilá, Joaquín
%A Oliveira, Mafalda
%A Pascual, Tomás
%A Perez-Garcia, Jose
%A Gonzàlez, Xavier
%A Canes, Jordi
%A Paré, Laia
%A Calvo, Isabel
%A Ciruelos, Eva
%A Muñoz, Montserrat
%A Virizuela, Juan A
%A Ruiz, Isabel
%A Andrés, Raquel
%A Perelló, Antonia
%A Martínez, Jerónimo
%A Morales, Serafín
%A Marín-Aguilera, Mercedes
%A Martínez, Débora
%A Quero, Juan C
%A Llombart-Cussac, Antonio
%A Prat, Aleix
%T Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
%D 2019
%U http://hdl.handle.net/10668/13391
%K Breast cancer
%K HER2
%K HER2-enriched
%K PAM50
%K cardiac safety
%K intrinsic subtypes
%K neoadjuvant
%~